KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Retained Earnings (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Retained Earnings for 16 consecutive years, with -$18.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 572.5% to -$18.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$18.1 million, a 572.5% decrease, with the full-year FY2025 number at -$18.1 million, down 572.5% from a year prior.
  • Retained Earnings was -$18.1 million for Q4 2025 at Halozyme Therapeutics, up from -$22.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $397.6 million in Q3 2024 to a low of -$433.7 million in Q1 2021.
  • A 5-year average of -$14.7 million and a median of -$2.0 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 267881.82% in 2021, then surged 610921.43% in 2022.
  • Halozyme Therapeutics' Retained Earnings stood at -$58.9 million in 2021, then soared by 343.1% to $143.2 million in 2022, then plummeted by 106.48% to -$9.3 million in 2023, then surged by 141.27% to $3.8 million in 2024, then plummeted by 572.5% to -$18.1 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Retained Earnings are -$18.1 million (Q4 2025), -$22.3 million (Q3 2025), and -$3.4 million (Q1 2025).